Akebia Therapeutics (AKBA) Cash & Equivalents (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Cash & Equivalents of $162.6 million for Q1 2026, up 43.39% year-over-year from $113.4 million in Q1 2025, and down 12.03% quarter-over-quarter from $184.8 million in Q4 2025.
Akebia Therapeutics (AKBA) Cash & Equivalents (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Cash & Equivalents for 14 consecutive years, with $162.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 43.39% year-over-year to $162.6 million; the TTM figure through Mar 2026 stood at $162.6 million (up 43.39% YoY), while the FY2025 annual figure was $184.8 million, up 256.36% from the prior year.
- Cash & Equivalents fell to $162.6 million in Q1 2026 per AKBA's latest filing, from $184.8 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $184.8 million in Q4 2025 and bottomed at $34.0 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $99.2 million across 5 years, with a median of $90.5 million in 2022.
- Annual changes were most pronounced in 2023 — Cash & Equivalents sank 67.86% — and 2025, when it soared 389.54%.
- Akebia Therapeutics' Cash & Equivalents stood at $90.5 million in 2022, then sank by 52.55% to $42.9 million in 2023, then advanced by 20.84% to $51.9 million in 2024, then surged by 256.36% to $184.8 million in 2025, then retreated by 12.03% to $162.6 million in 2026.
- Business Quant data shows AKBA's Cash & Equivalents at $162.6 million in Q1 2026, $184.8 million in Q4 2025, and $166.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 155.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 155.55 Mn |
| Mar 31, 2026 | 162.60 Mn |
| Dec 31, 2025 | 184.84 Mn |
| Sep 30, 2025 | 166.44 Mn |
| Jun 30, 2025 | 137.31 Mn |
| Mar 31, 2025 | 113.40 Mn |
| Dec 31, 2024 | 51.87 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 39.50 Mn |
| Mar 31, 2024 | 42.00 Mn |
| Dec 31, 2023 | 42.93 Mn |
| Sep 30, 2023 | 46.53 Mn |
| Jun 30, 2023 | 53.57 Mn |
| Mar 31, 2023 | 57.00 Mn |
| Dec 31, 2022 | 90.47 Mn |
| Sep 30, 2022 | 144.76 Mn |
| Jun 30, 2022 | 143.90 Mn |
| Mar 31, 2022 | 174.60 Mn |
| Dec 31, 2021 | 149.80 Mn |
| Sep 30, 2021 | 207.20 Mn |